PE70698A1 - Proteina quimerica de union a tnfo para el tratamiento del asma - Google Patents

Proteina quimerica de union a tnfo para el tratamiento del asma

Info

Publication number
PE70698A1
PE70698A1 PE1997000351A PE00035197A PE70698A1 PE 70698 A1 PE70698 A1 PE 70698A1 PE 1997000351 A PE1997000351 A PE 1997000351A PE 00035197 A PE00035197 A PE 00035197A PE 70698 A1 PE70698 A1 PE 70698A1
Authority
PE
Peru
Prior art keywords
protein
moles
igg
tnfo
asthma
Prior art date
Application number
PE1997000351A
Other languages
English (en)
Spanish (es)
Inventor
Louis Martin Renzetti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE70698A1 publication Critical patent/PE70698A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE1997000351A 1996-05-08 1997-05-05 Proteina quimerica de union a tnfo para el tratamiento del asma PE70698A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08

Publications (1)

Publication Number Publication Date
PE70698A1 true PE70698A1 (es) 1998-11-18

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000351A PE70698A1 (es) 1996-05-08 1997-05-05 Proteina quimerica de union a tnfo para el tratamiento del asma

Country Status (15)

Country Link
EP (1) EP0910413A2 (fr)
JP (1) JP2000510113A (fr)
KR (1) KR20000010825A (fr)
CN (1) CN1233189A (fr)
AR (1) AR007020A1 (fr)
AU (1) AU725408B2 (fr)
BR (1) BR9708928A (fr)
CA (1) CA2253557A1 (fr)
CO (1) CO4820397A1 (fr)
HR (1) HRP970224A2 (fr)
MA (1) MA24169A1 (fr)
PE (1) PE70698A1 (fr)
TR (1) TR199802238T2 (fr)
WO (1) WO1997041895A2 (fr)
ZA (1) ZA973843B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136988A0 (en) * 1997-12-29 2001-06-14 Regeneron Pharma Novel nucleic acid and polypeptide
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
CN101600450A (zh) 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP3488851A1 (fr) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Thérapies immunoablatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939121B2 (fr) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. Protéines liant le TNF
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (fr) * 1993-03-29 1994-09-30 David Banner Muteines du facteur de necrose tumoral
AU3111995A (en) * 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
CA2253557A1 (fr) 1997-11-13
MA24169A1 (fr) 1997-12-31
WO1997041895A2 (fr) 1997-11-13
ZA973843B (en) 1997-11-10
BR9708928A (pt) 2000-05-09
CN1233189A (zh) 1999-10-27
AU2776497A (en) 1997-11-26
KR20000010825A (ko) 2000-02-25
JP2000510113A (ja) 2000-08-08
AU725408B2 (en) 2000-10-12
EP0910413A2 (fr) 1999-04-28
WO1997041895A3 (fr) 1998-03-12
HRP970224A2 (en) 1998-04-30
AR007020A1 (es) 1999-10-13
CO4820397A1 (es) 1999-07-28
TR199802238T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
UY25897A1 (es) Preparación de proteínas de fusión con porciones de inmunoglobulinas
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
ATE168415T1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
RU94045281A (ru) Иммуноконъюгаты, способ получения иммуноконъюгата, фармацевтическая композиция, применение иммуноконъюгата
SE9100799D0 (sv) Recombinant human factor viii derivatives
SE8904239L (sv) Ett rekombinat, humant faktor-viii-derivat
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
UA40611C2 (uk) Імунокон'югат, спосіб його виготовлення, фармацевтична композиція
DE69129865D1 (de) Osteogene peptide
PE70698A1 (es) Proteina quimerica de union a tnfo para el tratamiento del asma
DK0871474T4 (da) Fremstilling af human insulin
EA199800221A1 (ru) Пептиды антисекреторного фактора, регулирующие патологические изменения проницаемости
DE69030937D1 (de) Mutanten von Interleukin-3
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты
DE69317886D1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
PT833917E (pt) Moleculas polipeptidicas do estadio pre-eritrocitario do paludismo
AU2002363465A1 (en) Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
CA2126182A1 (fr) Anticorps humanises reagissant avec le gpiib/iiia
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
NO20011263L (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
ATE317851T1 (de) Polypeptide mit aminosäuresequenzen aus dem n- terminalen bereich von gp116 von cytomegalovirus und deren verwendung bei der diagnostik, prophylaxe und therapie
Wines et al. The Fab/c fragment of IgG produced by cleavage at cyanocysteine residues
HUP0001579A2 (en) Cell surface molecule mediating cell adhesion and signal transmission
Kim et al. Construction and characterization of a single-chain immunoglobulin

Legal Events

Date Code Title Description
FD Application declared void or lapsed